Trial Profile
Phase II trial of durvalumab (MEDI4736) and tremelimumab in hormone receptor-positive, hypermutated metastatic breast cancer identified by whole exome sequencing
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 30 Dec 2021 Status changed from recruiting to completed.
- 08 Aug 2018 New trial record